Galapagos (GLPG)

• Market cap: $1.69B
• 1 day: -0.77%
• 5 days: -1.12%
• 1 month: 10.05%
• 3 months: -6.12%
• 6 months: -12.29%
• Year to date: -8.14%
• 1 year: -26.03%
• 5 years: -86.22%
• 10 years: -49.25%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Employees: 646

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

670% more call options, than puts

Call options by funds: $27.1M | Put options by funds: $3.52M

120% more capital invested

Capital invested by funds: $390M [Q3] → $857M (+$467M) [Q4]

26.59% more ownership

Funds ownership: 20.55% [Q3] → 47.14% (+26.59%) [Q4]

25% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

3% more funds holding

Funds holding: 78 [Q3] → 80 (+2) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 24

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $22 14% downside
• Avg. target: $22 14% downside
• High target: $22 14% downside

1 analyst rating

• positive: 0 0%
• neutral: 0 0%
• negative: 1 100%

Morgan Stanley Judah Frommer 33% 1-year accuracy 3 / 9 met price target

14% downside $22

Underweight Downgraded

14 Feb 2025